Andersson Anna K, Atkinson Sara E, Khanolkar-Young Saroj, Chaduvula Mehervani, Jain Suman, Suneetha Lavanya, Suneetha Sujai, Lockwood Diana N J
Department of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
Immunol Lett. 2007 Mar 15;109(1):72-5. doi: 10.1016/j.imlet.2007.01.004. Epub 2007 Feb 5.
Regulation of inflammation in leprosy may be influenced by local concentrations of active cortisol and inactive cortisone, whose concentrations are regulated by enzymes in the cortisol-cortisone shuttle. We investigated the cortisol-cortisone shuttle enzymes in the skin of leprosy patients with type 1 reactions (T1R), which are characterised by skin and nerve inflammation. Gene expression of the shuttle enzymes were quantified in skin biopsies from 15 leprosy patients with new T1R before and during prednisolone treatment and compared with levels in skin biopsies from 10 borderline leprosy patients without reactions. Gene expression of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2, which converts cortisol to cortisone, is down-regulated in skin from T1R lesions. However expression levels of 11beta-HSD type 1, which converts cortisone to cortisol, were similar in skin with and without reactions and did not change during anti-leprosy drug treatment. Prednisolone treatment of patients with reactions is associated with an upregulation of 11beta-HSD2 expression in skin. The down regulation of 11beta-HSD2 at the beginning of a reaction may be caused by pro-inflammatory cytokines in the leprosy reactional lesion and may be a local attempt to down-regulate inflammation. However in leprosy reactions this local response is insufficient and exogenous steroids are required to control inflammation.
麻风病炎症的调节可能受活性皮质醇和无活性可的松局部浓度的影响,其浓度由皮质醇 - 可的松穿梭系统中的酶调节。我们研究了1型反应(T1R)麻风病患者皮肤中的皮质醇 - 可的松穿梭酶,该反应以皮肤和神经炎症为特征。在15例新发生T1R的麻风病患者泼尼松龙治疗前和治疗期间的皮肤活检中,对穿梭酶的基因表达进行定量,并与10例无反应的边缘型麻风病患者皮肤活检中的水平进行比较。将皮质醇转化为可的松的2型11β-羟基类固醇脱氢酶(11β-HSD)的基因表达在T1R病变皮肤中下调。然而,将可的松转化为皮质醇的1型11β-HSD的表达水平在有反应和无反应的皮肤中相似,并且在抗麻风病药物治疗期间没有变化。对有反应的患者进行泼尼松龙治疗与皮肤中11β-HSD2表达上调有关。反应开始时11β-HSD2的下调可能是由麻风病反应性病变中的促炎细胞因子引起的,可能是局部下调炎症的尝试。然而,在麻风病反应中,这种局部反应是不够的,需要外源性类固醇来控制炎症。